MARKSANS · Concall Summary
MARKSANS PHARMA LIMITED
Marksans Pharma Limited reported strong financial results for Q1 FY27 during its earnings conference call held on August 13, 2026. Management stated that revenue reached INR841 crores, reflecting a 35.6% year-on-year increase, with the highest quarterly EBITDA of INR213 crores and PAT of INR159 crores. The company highlighted significant growth in Europe, particularly in the UK, which saw a 74.7% revenue increase year-on-year. Management noted the completion of the acquisition of QliniQ B.V., contributing approximately INR44 crores to revenue, and the establishment of Marksans Pharma Europe in Ireland and Marksans Pharma GmbH in Germany. North America contributed INR377 crores, growing 15.1% year-on-year, while Australia and New Zealand reported INR88 crores, up 53.7%. Management emphasized a focus on scaling operations, accelerating product launches, and improving profitability throughout FY27.
Management emphasized strong growth and profitability in the quarter.
View source filing →Earlier concalls
- 2026-08-12 — Marksans Pharma Limited reported strong financial performance for Q1FY27, achieving an all-time high quarterly EBITDA of…
- 2026-06-03 — Marksans Pharma Limited held its Q4 FY26 Earnings Conference Call on May 27, 2026, where management reported significant…
- 2026-05-26 — Marksans Pharma Limited reported significant financial achievements for FY26, with total income reaching approximately ₹…
See MARKSANS's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free